<DOC>
	<DOC>NCT01925209</DOC>
	<brief_summary>To evaluate the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM)</brief_summary>
	<brief_title>Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis, Inclusion Body</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Antibodies, Blocking</mesh_term>
	<criteria>Diagnosed with sporadic inclusion body myositis; Must be able to walk (assistive aids allowed, including intermittent use of wheelchair); Must not have other conditions that significantly limit ability to move around; Must not be using corticosteroids. Must not have used systemic corticosteroid (at daily dose &gt;=10mg prednisone) for the past 3 months; Must meet cardiovascular requirements; Must not be pregnant or nursing; Must not have a chronic active infection (e.g., HIV, hepatitis B or C, tuberculosis, etc); Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>sporadic inclusion body myositis,</keyword>
	<keyword>myositis,</keyword>
	<keyword>muscle wasting,</keyword>
	<keyword>controlled clinical trial,</keyword>
	<keyword>randomized,</keyword>
	<keyword>body mass,</keyword>
	<keyword>muscle function,</keyword>
	<keyword>strength,</keyword>
	<keyword>performance,</keyword>
	<keyword>physical function</keyword>
</DOC>